In a patient with serum creatinine 1.57 mg/dL and estimated glomerular filtration rate 44 mL/min, what is the appropriate dose, dosing interval, and duration of amoxicillin‑clavulanate (Augmentin) for an infected skin wound?

Dose Adjustment for Augmentin in Moderate Renal Impairment

For a patient with GFR 44 mL/min and infected skin wound, prescribe Augmentin 500 mg/125 mg orally every 12 hours for 5-7 days. 1

Rationale for Dosing

Your patient has moderate renal impairment (CKD Stage 3b) with a GFR of 44 mL/min. The standard Augmentin dose of 875/125 mg twice daily requires adjustment because amoxicillin clearance decreases significantly with declining renal function, while clavulanic acid clearance is less affected 2. This differential elimination creates a critical dosing challenge.

Key Pharmacokinetic Considerations

• Amoxicillin accumulation is pronounced in moderate renal impairment, with total body clearance decreasing more dramatically than clavulanic acid clearance 2
• At GFR 35-75 mL/min, the ratio of amoxicillin to clavulanic acid exposure increases to 5.3 (compared to 4.9 at normal GFR), indicating disproportionate amoxicillin accumulation 2
• Standard dosing prevents undue amoxicillin accumulation while maintaining adequate clavulanic acid concentrations 2

Specific Dosing Recommendation

Dose: Augmentin 500 mg/125 mg (not 875/125 mg)
Frequency: Every 12 hours
Duration: 5-7 days (depending on clinical response)

Why This Dose?

• The 500/125 mg formulation provides appropriate amoxicillin exposure without excessive accumulation at GFR 44 mL/min
• Maintains therapeutic clavulanic acid levels to inhibit beta-lactamase producing organisms
• The FDA label does not provide explicit renal dosing, but pharmacokinetic data strongly supports dose reduction at GFR <50 mL/min 2

Clinical Context for Infected Skin Wounds

Amoxicillin-clavulanate is guideline-recommended first-line therapy for infected skin wounds, particularly when mixed aerobic-anaerobic flora is suspected 3. The combination provides:

• Coverage of Staphylococcus aureus (including beta-lactamase producers)
• Coverage of Streptococcus pyogenes
• Anaerobic coverage for deeper tissue involvement
• Clinical efficacy demonstrated in 94% of skin infections 4

Duration Considerations

• 5-7 days is typically sufficient for uncomplicated infected skin wounds with appropriate source control
• Extend to 7-10 days if:
  • Significant surrounding cellulitis (>5 cm erythema)
  • Systemic signs present (fever >38.5°C, tachycardia >110 bpm)
  • Delayed clinical response at 48-72 hours
  • Immunocompromised status

Critical Monitoring Points

Watch for Treatment Failure Indicators

• No improvement by 48-72 hours suggests need for culture and possible MRSA coverage
• Worsening erythema, purulent drainage, or systemic toxicity requires immediate reassessment 3
• Consider imaging if necrotizing infection suspected (severe pain out of proportion, crepitus, rapid progression)

Renal Function Monitoring

• Do not use this dose if GFR drops below 30 mL/min - further dose reduction to 500/125 mg every 24 hours required
• Monitor for drug accumulation signs: nausea, diarrhea (occurs in 9% of patients) 4

Common Pitfalls to Avoid

1. Do NOT use 875/125 mg formulation at this GFR - excessive amoxicillin accumulation risk
2. Do NOT extend dosing interval beyond 12 hours at GFR 44 mL/min - this maintains adequate clavulanic acid levels
3. Do NOT substitute with other Augmentin formulations (like ES-600 suspension) as they contain different clavulanic acid ratios and are not interchangeable 1
4. Administer at the start of meals to minimize GI intolerance and enhance clavulanic acid absorption 1

When to Escalate Therapy

If MRSA is suspected or confirmed (purulent drainage, prior MRSA history, treatment failure):

• Add doxycycline 100 mg twice daily or trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily 3
• These agents require no dose adjustment at GFR 44 mL/min

Tetanus Prophylaxis

Ensure tetanus vaccination status is current - administer Tdap if >10 years since last dose for clean wounds, or >5 years for contaminated wounds 3